Sale Of Australia's HeartWare To Thoratec Of U.S. Canceled
This article was originally published in PharmAsia News
Executive Summary
Australia's HeartWare International, maker of medical devices, may not be sold soon after all. The U.S. Federal Trade Commission indicated it would challenge the purchase, leading Thoratec to cancel the deal. The firm's CEO said the board decided not to pursue a deal it figured would be protracted, costly and unpredictable. The FTC was concerned the merger of the two companies would lead to a monopoly of the market for left ventricular assist devices, which are used in patients with advanced heart failure. (Click here for more
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.